Ascentage Pharma Group International (NASDAQ:AAPG) Hits New 1-Year Low – Should You Sell?

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) reached a new 52-week low during trading on Friday . The stock traded as low as $16.48 and last traded at $16.78, with a volume of 173232 shares traded. The stock had previously closed at $17.05.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the company. China Intl Cap raised Ascentage Pharma Group International to a “strong-buy” rating in a research report on Monday, April 6th. Deutsche Bank Aktiengesellschaft started coverage on shares of Ascentage Pharma Group International in a research note on Friday, April 24th. They set a “buy” rating and a $40.00 target price on the stock. B. Riley Financial began coverage on shares of Ascentage Pharma Group International in a research report on Wednesday, June 10th. They issued a “buy” rating and a $45.00 price target for the company. Raymond James Financial reissued a “buy” rating on shares of Ascentage Pharma Group International in a research note on Wednesday, June 10th. Finally, BTIG Research restated a “buy” rating and set a $48.00 target price on shares of Ascentage Pharma Group International in a research note on Monday, June 15th. Two analysts have rated the stock with a Strong Buy rating and eight have given a Buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $46.43.

Ascentage Pharma Group International Price Performance

The firm has a 50-day moving average of $20.43 and a 200-day moving average of $23.76. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.77 and a current ratio of 1.79.

Ascentage Pharma Group International (NASDAQ:AAPG) last posted its quarterly earnings results on Wednesday, March 25th. The company reported ($0.52) EPS for the quarter. The company had revenue of $24.72 million during the quarter. As a group, research analysts anticipate that Ascentage Pharma Group International – Unsponsored ADR will post -0.96 EPS for the current year.

Hedge Funds Weigh In On Ascentage Pharma Group International

Several hedge funds have recently modified their holdings of the stock. Citadel Advisors LLC bought a new position in shares of Ascentage Pharma Group International during the third quarter worth $383,000. Hsbc Holdings PLC bought a new stake in Ascentage Pharma Group International in the 2nd quarter valued at $391,000. UBS Group AG lifted its stake in Ascentage Pharma Group International by 149.4% in the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock worth $716,000 after purchasing an additional 10,988 shares in the last quarter. Finally, XY Capital Ltd boosted its holdings in shares of Ascentage Pharma Group International by 224.2% during the 3rd quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock valued at $707,000 after purchasing an additional 12,530 shares during the last quarter.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.